ALK and non-small cell lung carcinoma: The ASCEND-8 bioequivalence trial showed similar pharmacokinetics and better gastrointestinal safety profile of lower dose ceritinib − 450 mg with food, versus ceritinib 750 mg [6, 7] Ceritinib 450 mg with food was approved in HK for the first-line treatment of patients with ALK + advanced NSCLC in May 2018.